Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed) (c. 2377)

[F1 ANNEX I U.K. LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES FOR WHICH MAXIMUM RESIDUE LIMITS HAVE BEEN FIXED

Textual Amendments

F1 Substituted by Commission Regulation (EC) No 508/1999 of 4 March 1999 amending Annexes I to IV to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.

1. Anti-infectious agents U.K.

1.1. Chemotheurapeutics U.K.

1.1.1. Sulfonamides U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
All substances belonging to the sulfonamide group	Parent drug	All food-producing species	100 μg/kg	Muscle	The combined total residues of all substances within the sulfonamide group should not exceed 100 μg/kg
			100 μg/kg	Fat
			100 μg/kg	Liver
			100 μg/kg	Kidney
		Bovine, ovine, caprine	100 μg/kg	Milk

1.1.2. Diamino pyrimidine derivatives U.K.

a [F2 For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .
b For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .]
Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Baquiloprim	Baquiloprim	Bovine	10 μg/kg	Fat
			300 μg/kg	Liver
			150 μg/kg	Kidney
			30 μg/kg	Milk
		Porcine	40 μg/kg	Skin and fat
			50 μg/kg	Liver
			50 μg/kg	Kidney
[F3 Trimethoprim	Trimethoprim	All food producing species except equidae	50 μg/kg	Fat a	Not for use in animals from which eggs are produced for human consumption
			50 μg/kg	Muscle  b
			50 μg/kg	Liver
			50 μg/kg	Kidney
			50 μg/kg	Milk
		Equidae	100 μg/kg	Muscle
			100 μg/kg	Fat
			100 μg/kg	Liver
			100 μg/kg	Kidney]

Textual Amendments

F2 Inserted by Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F3 Substituted by Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2. Antibiotics U.K.

1.2.1. Penicillins U.K.

a [F4 For intramammary use only.
b [F5 Not for use in animals from which eggs are produced for human consumption.] ]
Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Amoxicyllin	Amoxicyllin	All food-producing species	50 μg/kg	Muscle
			50 μg/kg	Fat
			50 μg/kg	Liver
			50 μg/kg	Kidney
			4 μg/kg	Milk
Ampicillin	Ampicillin	All food-producing species	50 μg/kg	Muscle
			50 μg/kg	Fat
			50 μg/kg	Liver
			50 μg/kg	Kidney
			4 μg/kg	Milk
Benzylpenicillin	Benzylpenicillin	All food-producing species	50 μg/kg	Muscle
			50 μg/kg	Fat
			50 μg/kg	Liver
			50 μg/kg	Kidney
			4 μg/kg	Milk
Cloxacillin	Cloxacillin	All food-producing species	300 μg/kg	Muscle
			300 μg/kg	Fat
			300 μg/kg	Liver
			300 μg/kg	Kidney
			30 μg/kg	Milk
Dicloxacillin	Dicloxacillin	All food-producing species	300 μg/kg	Muscle
			300 μg/kg	Fat
			300 μg/kg	Liver
			300 μg/kg	Kidney
			30 μg/kg	Milk
[F6 Nafcillin	Nafcillin	All ruminants a	300 μg/kg	Muscle
			300 μg/kg	Fat
			300 μg/kg	Liver
			300 μg/kg	Kidney
			30 μg/kg	Milk]
Oxacillin	Oxacillin	All food-producing species	300 μg/kg	Muscle
			300 μg/kg	Fat
			300 μg/kg	Liver
			300 μg/kg	Kidney
			30 μg/kg	Milk
Penethamate	Benzylpenicillin	Bovine	50 μg/kg	Muscle
			50 μg/kg	Fat
			50 μg/kg	Liver
			50 μg/kg	Kidney
			4 μg/kg	Milk
[F7		Porcine	50 μg/kg	Muscle
			50 μg/kg	Fat
			50 μg/kg	Liver
			50 μg/kg	Kidney	]
[F8		All mammalian-food producing species	50 μg/kg	Muscle
			50 μg/kg	Fat
			50 μg/kg	Liver
			50 μg/kg	Kidney
			4 μg/kg	Milk	]
[F9 Phenoxymethylpenicillin	Phenoxymethylpenicillin	Porcine	25 μg/kg	Muscle
			25 μg/kg	Liver
			25 μg/kg	Kidney
		[F5 Poultry b	25  μg/kg	Muscle
			25  μg/kg	Skin + fat
			25  μg/kg	Liver
			25  μg/kg	Kidney	] ]

Textual Amendments

F4 Inserted by Commission Regulation (EC) No 546/2004 of 24 March 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F5 Inserted by Commission Regulation (EC) No 1299/2005 of 8 August 2005 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards phenoxymethylpenicillin, phoxim, norgestomet and thiamphenicol (Text with EEA relevance).

F6 Substituted by Commission Regulation (EC) No 546/2004 of 24 March 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F7 Inserted by Commission Regulation (EC) No 2757/1999 of 22 December 1999 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F8 Inserted by Commission Regulation (EC) No 1148/2005 of 15 July 2005 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards penethamate (Text with EEA relevance).

F9 Inserted by Commission Regulation (EC) No 1286/2000 of 19 June 2000 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2.2. Cephalosporins U.K.

a [F10 For porcine species this MRL relates to ‘ skin and fat in natural proportions ’ .]
Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[F11 Cefacetrile	Cefacetrile	Bovine	125 μg/kg	Milk	For intramammary use only]
[F12 Cefalexin	Cefalexin	Bovine	200 μg/kg	Muscle
			200 μg/kg	Fat
			200 μg/kg	Liver
			1 000  μg/kg	Kidney
			100 μg/kg	Milk	]
[F13 Cefalonium	Cefalonium	Bovine	20 μg/kg	Milk	]
[F14 Cefapirin	Sum of cephapirin and desacetylcephapirin	Bovine	50 μg/kg	Muscle
			50 μg/kg	Fat
			100 μg/kg	Kidney
			60 μg/kg	Milk	]
Cefazolin	Cefazolin	Bovine, ovine, caprine	50 μg/kg	Milk
[F15 Cefoperazone	Cefoperazone	Bovine	50 μg/kg	Milk	]
Cefquinome	Cefquinome	Bovine	50 μg/kg	Muscle
			50 μg/kg	Fat
			100 μg/kg	Liver
			200 μg/kg	Kidney
			20 μg/kg	Milk
[F16		Porcine	50 μg/kg	Muscle
			50 μg/kg	Skin + fat
			100 μg/kg	Liver
			200 μg/kg	Kidney	]
[F17		Equidae	50 μg/kg	Muscle
			50 μg/kg	Fat
			100 μg/kg	Liver
			200 μg/kg	Kidney	]
[F18 Ceftiofur	Sum of all residues retaining the betalactam structure expressed as desfuroylceftiofur	All mammalian food-producing species	1 000  μg/kg	Muscle
			2 000  μg/kg	Fat a
			2 000  μg/kg	Liver
			6 000  μg/kg	Kidney
			100  μg/kg	Milk]

Textual Amendments

F10 Inserted by Commission Regulation (EC) No 1231/2006 of 16 August 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards ceftiofur and polyoxyethylene sorbitan monooleate and trioleate (Text with EEA relevance).

F11 Inserted by Commission Regulation (EC) No 2162/2001 of 7 November 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F12 Inserted by Commission Regulation (EC) No 2728/1999 of 20 December 1999 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F13 Inserted by Commission Regulation (EC) No 61/2003 of 15 January 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F14 Inserted by Commission Regulation (EC) No 1553/2001 of 30 July 2001 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F15 Inserted by Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F16 Inserted by Commission Regulation (EC) No 1931/1999 of 9 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F17 Inserted by Commission Regulation (EC) No 2145/2003 of 8 December 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F18 Substituted by Commission Regulation (EC) No 1231/2006 of 16 August 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards ceftiofur and polyoxyethylene sorbitan monooleate and trioleate (Text with EEA relevance).

1.2.3. Quinolones U.K.

a [F2 For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .
b For porcine species this MRL relates to ‘ skin and fat in natural proportions ’ .
c [F19 Not for use in animals from which milk or eggs are produced for human consumption; MRLs for fat, liver and kidney do not apply to fin fish.
d For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .] ]
Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[F3 Danofloxacin	Danofloxacin	[X1 All food producing species except bovine, ovine, caprine, porcine and poultry]	100 μg/kg	Muscle b
			50 μg/kg	Fat a
			200 μg/kg	Liver
			200 μg/kg	Kidney
		Bovine, ovine, caprine	200 μg/kg	Muscle
			100 μg/kg	Fat
			400 μg/kg	Liver
			400 μg/kg	Kidney
			30 μg/kg	Milk
		Poultry	200 μg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			100 μg/kg	Skin and fat
			400 μg/kg	Liver
			400 μg/kg	Kidney
Difloxacin	Difloxacin	All food producing species except bovine, ovine, caprine and poultry	300 μg/kg	Muscle b
			100 μg/kg	Fat
			800 μg/kg	Liver
			600 μg/kg	Kidney
		Bovine, ovine, caprine	400 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			100 μg/kg	Fat
			1 400  μg/kg	Liver
			800 μg/kg	Kidney
		Porcine	400 μg/kg	Muscle
			100 μg/kg	Skin and fat
			800 μg/kg	Liver
			800 μg/kg	Kidney
		Poultry	300 μg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			400 μg/kg	Skin and fat
			1 900  μg/kg	Liver
			600 μg/kg	Kidney
Enrofloxacin	Sum of enrofloxacin and ciprofloxacin	All food producing species except bovine, ovine, caprine, porcine, rabbits and poultry	100 μg/kg	Muscle b
			100 μg/kg	Fat
			200 μg/kg	Liver
			200 μg/kg	Kidney
		Bovine, ovine, caprine	100 μg/kg	Muscle
			100 μg/kg	Fat
			300 μg/kg	Liver
			200 μg/kg	Kidney
			100 μg/kg	Milk
		Porcine, rabbits	100 μg/kg	Muscle
			100 μg/kg	Fat a
			200 μg/kg	Liver
			300 μg/kg	Kidney
		Poultry	100 μg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			100 μg/kg	Skin and fat
			200 μg/kg	Liver
			300 μg/kg	Kidney
Flumequine	Flumequine	All food producing species except bovine, ovine, caprine, porcine, poultry and fin fish	200 μg/kg	Muscle
			250 μg/kg	Fat
			500 μg/kg	Liver
			1 000  μg/kg	Kidney
		Bovine, porcine, ovine, caprine	200 μg/kg	Muscle
			300 μg/kg	Fat a
			500 μg/kg	Liver
			1 500  μg/kg	Kidney
			50 μg/kg	Milk
		Poultry	400 μg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			250 μg/kg	Skin and fat
			800 μg/kg	Liver
			1 000  μg/kg	Kidney
		Fin fish	600 μg/kg	Muscle and skin in natural proportion	]
[F20 Marbofloxacin	Marbofloxacin	Bovine	150 μg/kg	Muscle
			50 μg/kg	Fat
			150 μg/kg	Liver
			150 μg/kg	Kidney
			75 μg/kg	Milk
		Porcine	150 μg/kg	Muscle
			50 μg/kg	Skin and fat
			150 μg/kg	Liver
			150 μg/kg	Kidney	]
[F21 Oxolinic acid	Oxolinic acid	Porcine	100 μg/kg	Muscle
			50 μg/kg	Skin and fat
			150 μg/kg	Liver
			150 μg/kg	Kidney
		Chicken	100 μg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			50 μg/kg	Skin and fat
			150 μg/kg	Liver
			150 μg/kg	Kidney
		Fin fish	100 μg/kg	Muscle and skin in natural proportions
		[F19 All food-producing species c	100 μg/kg	Muscle a
			50 μg/kg	Fat d
			150 μg/kg	Liver
			150 μg/kg	Kidney	] ]
Sarafloxacin	Sarafloxacin	Chicken	10 μg/kg	Skin and fat
			100 μg/kg	Liver
		Salmonidae	30 μg/kg	Muscle and skin in natural proportions

Editorial Information

X1 Substituted by Corrigendum to Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 172 of 2 July 2002).

Textual Amendments

F19 Inserted by Commission Regulation (EC) No 1356/2005 of 18 August 2005 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards oxolinic acid and morantel (Text with EEA relevance).

F20 Inserted by Commission Regulation (EC) No 2338/2000 of 20 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F21 Inserted by Commission Regulation (EC) No 739/2003 of 28 April 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2.4. Macrolides U.K.

a [F2 For fin fish this MRL relates to a ‘ muscle and skin in natural proportions ’ .
b For procine species this MRL relates to ‘ skin and fat in natural proportions ’ .
c For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .
d [F22 [X2 Not for use in animals from which milk is produced for human consumption.] ]
e [F23 Not for use in animals from which milk is produced for human consumption.] ]
Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[F24 Acetylisovaleryltylosin	Sum of acetyl-isovaleryltylosin and 3-O-acetyltylosin	Porcine	50 μg/kg	Muscle
			50 μg/kg	Skin and fat
			50 μg/kg	Liver
			50 μg/kg	Kidney
		[F23 Poultry e	50 μg/kg	Skin + fat
			50 μg/kg	Liver	] ]
[F3 Erythromycin	Erythromicyin A	All food producing species	200 μg/kg	Muscle  a
			200 μg/kg	Fat  b
			200 μg/kg	Liver
			200 μg/kg	Kidney
			40 μg/kg	Milk
			150 μg/kg	Eggs	]
Spiramycin	Sum of spiramycin and neospiramycin	Bovine	200 μg/kg	Muscle
			300 μg/kg	Fat
			300 μg/kg	Liver
			300 μg/kg	Kidney
			200 μg/kg	Milk
		Chicken	200 μg/kg	Muscle
			300 μg/kg	Skin and fat
			400 μg/kg	Liver
[F25	Spiramycin 1	Porcine	250 μg/kg	Muscle
			2 000  μg/kg	Liver
			1 000  μg/kg	Kidney	]
[F3 Tilmicosin	Tilmicosin	All food producing species except poultry	50 μg/kg	Muscle  a
			50 μg/kg	Fat  b
			1 000  μg/kg	Liver
			1 000  μg/kg	Kidney
			50 μg/kg	Milk
		Poultry	75 μg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			75 μg/kg	Sin and fat
			1 000  μg/kg	Liver
			250 μg/kg	Kidney
[F22 [X2 Tulathromycin	(2R,3S,4R,5R,8R,10R,11R,12S, 13S,14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D-xylo-hexopy-ranosyl]oxy]-1-oxa-6-azacyclopent-decan-15-one expressed as tulathromycin equivalents	Bovine d	100  μg/kg	Fat
			3 000  μg/kg	Liver
			3 000  μg/kg	Kidney
		Porcine	100  μg/kg	Skin + fat
			3 000  μg/kg	Liver
			3 000  μg/kg	Kidney	] ]
Tylosin	Tylosin A	All food producing species	100 μg/kg	Fat  c
			100 μg/kg	Muscle  a
			100 μg/kg	Liver
			100 μg/kg	Kidney
			50 μg/kg	Milk
			200 μg/kg	Eggs	]

Editorial Information

X2 Substituted by Corrigendum to Commission Regulation (EC) No 1101/2004 of 10 June 2004 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Union L 211 of 12 June 2004).

Textual Amendments

F22 Inserted by Commission Regulation (EC) No 1101/2004 of 10 June 2004 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F23 Inserted by Commission Regulation (EC) No 1518/2005 of 19 September 2005 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards acetylisovaleryltylosin and fluazuron (Text with EEA relevance).

F24 Inserted by Commission Regulation (EC) No 77/2002 of 17 January 2002 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F25 Inserted by Commission Regulation (EC) No 2593/1999 of 8 December 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2.5. Florfenicol and related compounds U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[F3 Florfenicol	Sum of florfenicol and its metabolites measured as florfenicol-amine	All food producing species except bovine, ovine, caprine, porcine, poultry and fin fish	100 μg/kg	Muscle
			200 μg/kg	Fat
			2 000  μg/kg	Liver
			300 μg/kg	Kidney
		Bovine, ovine, caprine	200 μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			[X3 3 000 μg/kg]	[X3 Liver]
			300 μg/kg	Kidney
		Porcine	300 μg/kg	Muscle
			500 μg/kg	Skin and fat
			2 000  μg/kg	Liver
			500 μg/kg	Kidney
		Poultry	100 μg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			200 μg/kg	Skin and fat
			2 500  μg/kg	Liver
			750 μg/kg	Kidney
		Fin fish	1 000  μg/kg	Muscle and skin in natural proportions	]
Thiamphenicol	Thiamphenicol	Bovine	50 μg/kg	Muscle
			50 μg/kg	Fat
			50 μg/kg	Liver
			50 μg/kg	Kidney
			50 μg/kg	Milk
		Chicken	50 μg/kg	Muscle
		Not for use in animals from which eggs are produced for human consumption	50 μg/kg	Skin and fat
			50 μg/kg	Liver
			50 μg/kg	Kidney

Editorial Information

X3 Substituted by Corrigendum to Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 172 of 2 July 2002).

1.2.6. Tetracyclines U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Chlortetracycline	Sum of parent drug and its 4- epimer	All food-producing species	100 μg/kg	Muscle
			300 μg/kg	Liver
			600 μg/kg	Kidney
			100 μg/kg	Milk
			200 μg/kg	Eggs
Doxycycline	Doxycycline	Bovine	100 μg/kg	Muscle
		Not for use in animals from which milk is produced for human consumption	300 μg/kg	Liver
			600 μg/kg	Kidney
		Porcine	100 μg/kg	Muscle
			300 μg/kg	Skin and fat
			300 μg/kg	Liver
			600 μg/kg	Kidney
		Poultry	100 μg/kg	Muscle
		Not for use in animals from which eggs are produced for human consumption	300 μg/kg	Skin and fat
			300 μg/kg	Liver
			600 μg/kg	Kidney
Oxytetracycline	Sum of parent drug and its 4-epimer	All food-producing species	100 μg/kg	Muscle
			300 μg/kg	Liver
			600 μg/kg	Kidney
			100 μg/kg	Milk
			200 μg/kg	Eggs
Tetracycline	Sum of parent drug and its 4-epimer	All food-producing species	100 μg/kg	Muscle
			300 μg/kg	Liver
			600 μg/kg	Kidney
			100 μg/kg	Milk
			200 μg/kg	Eggs

1.2.7. Naphtalene-ringed ansamycin U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Rifaximin	Rifaximin	Bovine	60 μg/kg	Milk

1.2.8. Pleuromutilines U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[F12 Tiamulin	Sum of metabolites that may be hydrolysed to 8-a-hydroxymutilin	Porcine	100 μg/kg	Muscle
			500 μg/kg	Liver
		Chicken	100 μg/kg	Muscle
			100 μg/kg	Skin and fat
			1 000  μg/kg	Liver
		[F20 Rabbits	100 μg/kg	Muscle
			500 μg/kg	Liver	]
		[F15 Turkey	100 μg/kg	Muscle
			100 μg/kg	Skin and fat
			300 μg/kg	Liver	]
	Tiamulin		1 000  μg/kg	Eggs	]
Valnemulin	Valnemulin	Porcine	50 μg/kg	Muscle
			500 μg/kg	Liver
			100 μg/kg	Kidney

[F26 1.2.9. Lincosamides U.K.

a [F2 For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .
b For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .] ]
Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[F3 Lincomycin	Lincomicyn	All food producing species	50 μg/kg	Fat  a
			100 μg/kg	Muscle  b
			500 μg/kg	Liver
			1 500  μg/kg	Kidney
			150 μg/kg	Milk
			50 μg/kg	Eggs	]
[F20 Pirlimycin	Pirlimycin	Bovine	100 μg/kg	Muscle
			100 μg/kg	Fat
			1 000  μg/kg	Liver
			400 μg/kg	Kidney
			100 μg/kg	Milk
		Porcine	100 μg/kg	Muscle
			50 μg/kg	Skin and fat
			500 μg/kg	Liver
			1 500  μg/kg	Kidney
		Chicken	100 μg/kg	Muscle
			50 μg/kg	Skin and fat
			500 μg/kg	Liver
			1 500  μg/kg	Kidney
			50 μg/kg	Eggs	]

Textual Amendments

F26 Inserted by Commission Regulation (EC) No 804/1999 of 16 April 1999 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[F16 1.2.10. Aminoglycosides U.K.

a [F2 For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .
b For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .
c [F27 Not for use in animals from which eggs are produced for human consumption.] ] ]
Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Apramycin	Apramycin	Bovine	1 000  μg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			1 000  μg/kg	Fat
			10 000  μg/kg	Liver
			20 000  μg/kg	Kidney
[F28 Dihydrostreptomycin	Dihydrostreptomycin	Bovine, ovine	500 μg/kg	Muscle
			500 μg/kg	Fat
			500 μg/kg	Liver
			1 000  μg/kg	Kidney
			200 μg/kg	Milk
		Porcine	500 μg/kg	Muscle
			500 μg/kg	Skin and fat
			500 μg/kg	Liver
			1 000  μg/kg	Kidney
		[F29 All ruminants	500  μg/kg	Muscle
			500  μg/kg	Fat
			500  μg/kg	Liver
			1 000  μg/kg	Kidney
			200  μg/kg	Milk	] ]
[F30 Gentamicin	Sum of gentamicin C1, gentamicin C1a, gentamicin C2 and gentamicin C2a	Bovine	50 μg/kg	Muscle
			50 μg/kg	Fat
			200 μg/kg	Liver
			750 μg/kg	Kidney
			100 μg/kg	Milk
		Porcine	50 μg/kg	Muscle
			50 μg/kg	Skin and fat
			200 μg/kg	Liver
			750 μg/kg	Kidney	]
[F27 Kanamycin	Kanamycin A	All food producing species except fish c	100 μg/kg	Muscle
			100 μg/kg	Fat a
			600 μg/kg	Liver
			2 500  μg/kg	Kidney
			150 μg/kg	Milk	]
[F2 Neomycin (including framycetin)	Neomycin B	All food producing species	500 μg/kg	Fat  a
			500 μg/kg	Muscle  b
			500 μg/kg	Liver
			5 000  μg/kg	Kidney
			1 500  μg/kg	Milk
			500 μg/kg	Eggs	]
[F3 Paromomycin	Paromomycin	All food producing species	500 μg/kg	Muscle b	Not for use in animals from which milk or eggs are produced for human consumption
			1 500  μg/kg	Liver
			1 500  μg/kg	Kidney
Spectinomycin	Spectinomycin	All food producing species except ovine	500 μg/kg	Fat a	Not for use in animals from which eggs are produced for human consumption
			300 μg/kg	Muscle  b
			1 000  μg/kg	Liver
			5 000  μg/kg	Kidney
			200 μg/kg	Milk
		Ovine	300 μg/kg	Muscle
			500 μg/kg	Fat
			2 000  μg/kg	Liver
			5 000  μg/kg	Kidney
			200 μg/kg	Milk]
[F28 Streptomycin	Streptomycin	Bovine, ovine	500 μg/kg	Muscle
			500 μg/kg	Fat
			500 μg/kg	Liver
			1 000  μg/kg	Kidney
			200 μg/kg	Milk
		Porcine	500 μg/kg	Muscle
			500 μg/kg	Skin and fat
			500 μg/kg	Liver
			1 000  μg/kg	Kidney	]

Textual Amendments

F27 Inserted by Commission Regulation (EC) No 324/2004 of 25 February 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F28 Inserted by Commission Regulation (EC) No 1530/2002 of 27 August 2002 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F29 Inserted by Commission Regulation (EC) No 6/2006 of 5 January 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards dihydrostreptomycin, tosylchloramide sodium and Piceae turiones recentes extractum (Text with EEA relevance).

F30 Inserted by Commission Regulation (EC) No 868/2002 of 24 May 2002 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[F25 1.2.11. Other antibiotics U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Novobiocin	Novobiocin	Bovine	50 μg/kg	Milk	]

[F31 1.2.12. Polypeptides U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Bacitracin	Sum of bacitracin A, bacitracin B, and bacitracin C	Bovine	100 μg/kg	Milk
[F32		Rabbits	150 μg/kg	Muscle
			150 μg/kg	Fat
			150 μg/kg	Liver
			150 μg/kg	Kidney	] ]

Textual Amendments

F32 Inserted by Commission Regulation (EC) No 544/2003 of 27 March 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Textual Amendments

F31 Inserted by Commission Regulation (EC) No 1478/2001 of 18 July 2001 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[F14 1.2.13. Beta-lactamase inhibitors U.K.

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Clavulanic acid	Clavulanic acid	Bovine	100 μg/kg	Muscle
			100 μg/kg	Fat
			200 μg/kg	Liver
			400 μg/kg	Kidney
			200 μg/kg	Milk
		Porcine	100 μg/kg	Muscle
			100 μg/kg	Skin and fat
			200 μg/kg	Liver
			400 μg/kg	Kidney	]

[F2 1.2.14. Polymyxins U.K.

a For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .
b For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .] ]
Pharmacologically active substance	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Colistin	Colistin	All food producing species	150 μg/kg	Fat  a
			150 μg/kg	Muscle  b
			150 μg/kg	Liver
			200 μg/kg	Kidney
			50 μg/kg	Milk
			300 μg/kg	Eggs